Table 2 Stromal and epithelial periostin expression in prostate cancer and clinico-pathological parameters of the test cohort
From: Periostin is up-regulated in high grade and high stage prostate cancer
| Â | Total n (%) | Periostin stromal low n (%) | Periostin stromal high n (%) | Periostin epithelial low n (%) | Periostin epithelial high n (%) | p-values stromal/epithelial |
|---|---|---|---|---|---|---|
All cases | 325 (100) | 224 (68.9) | 101 (31.1) | 189 (58.2) | 136 (41.8) | Â |
Age | Â | Â | Â | Â | Â | 0.120/ 1.000 |
≤ 64 | 165 (50.8) | 107 (64.8) | 58 (35.2) | 96 (58.2) | 69 (41.8) |  |
>64 | 160 (49.2) | 117 (73.1) | 43 (26.9) | 93 (58.1) | 67 (41.9) | Â |
pT-status | Â | Â | Â | Â | Â | 0.710/0.048 |
pT2 | 205 (63.1) | 143 (69.8) | 62 (30.2) | 128 (62.4) | 77 (37.6) | Â |
pT3/4 | 120 (36.9) | 81 (67.5) | 39 (32.5) | 61 (50.8) | 59 (49.2) | Â |
Gleason score | Â | Â | Â | Â | Â | 0.011/ 0.007 |
3-6 | 50 (15.4) | 40 (80.0) | 10 (20.0) | 35 (70.0) | 15 (30.0) | Â |
7 | 194 (59.7) | 136 (70.1) | 58 (29.9) | 116 (59.8) | 78 (40.2) | Â |
8-10 | 81 (24.9) | 48 (59.3) | 33 (40.7) | 38 (46.9) | 43 (53.1) | Â |
Residual tumour a | Â | Â | Â | Â | Â | 0.451/ 0.634 |
R0 | 207 (63.7) | 139 (67.1) | 68 (32.9) | 119 (57.5) | 88 (42.5) | Â |
R1 | 112 (34.5) | 80 (71.4) | 32 (28.6) | 68 (60.7) | 44 (39.3) | Â |